Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod ...
Leadership
Michael Kevin Handley
CEO & Director
Lisa G. Wolf
CFO and Principal Financial & Principal Accounting Officer
